Cargando…
What is the impact of acquired immunity on the transmission of schistosomiasis and the efficacy of current and planned mass drug administration programmes?
Schistosomiasis causes severe morbidity in many countries with endemic infection with the schistosome digenean parasites in Africa and Asia. To control and eliminate the disease resulting from infection, regular mass drug administration (MDA) is used, with a focus on school-aged children (SAC; 5–14...
Autores principales: | Kura, Klodeta, Hardwick, Robert J., Truscott, James E., Anderson, Roy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635407/ https://www.ncbi.nlm.nih.gov/pubmed/34851952 http://dx.doi.org/10.1371/journal.pntd.0009946 |
Ejemplares similares
-
The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?
por: Kura, Klodeta, et al.
Publicado: (2020) -
Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination
por: Kura, Klodeta, et al.
Publicado: (2019) -
Human population movement can impede the elimination of soil-transmitted helminth transmission in regions with heterogeneity in mass drug administration coverage and transmission potential between villages: a metapopulation analysis
por: Vegvari, Carolin, et al.
Publicado: (2019) -
Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies
por: Kura, Klodeta, et al.
Publicado: (2021) -
Individual longitudinal compliance to neglected tropical disease mass drug administration programmes, a systematic review
por: Maddren, Rosie, et al.
Publicado: (2023)